World

Japan's opposition party re-elects Tamaki as leader

Sep 03, 2023

Tokyo [Japan], September 3: Japan's opposition Democratic Party for the People (DPP) has re-elected its incumbent head Yuichiro Tamaki as the leader.
Tamaki, securing a decisive victory over the party's acting chief Seiji Maehara, was re-elected as the party's leader for a new three-year term in the leadership election on Saturday.
Tamaki, 54, whose term is until the end of September 2026, scooped up 80 points, more than the majority necessary to win out of the 111 points allocated to the voters, while Maehara garnered 31 points.
In his victory speech, Tamaki expressed his commitment to hear the opinions of different relevant parties for improvements in terms of issues exposed during the leadership election, in preparation for the upcoming general elections.
According to local media outlets, the five-term House of Representatives member also said he has no plans to become a Cabinet member, alluding to the potential reshuffle.
Analysts here pointed out that the election revealed a sharpening of ideological differences within the party, and that its future development will now be closely watched in Japan's political landscape.
In September 2020, Japan's largest opposition party emerged following a merger of the Constitutional Democratic Party (CDP) and the then DPP. The party retained the name of CDP.
However, over 10 members of the Japanese parliament, including Tamaki, chose not to join the CDP and instead established the new DPP. In December of the same year, Tamaki was elected as the leader of this newly formed party.
Source: Xinhua

More news

Concept Medical Announces Successful SIRONA Trial Results, Demonstrating Sirolimus-Coated Balloon as a Promising Alternative for PAD Treatment

Tampa (Florida) [US], January 7: Concept Medical Inc., a global leader in innovative drug-delivery technology, proudly reports positive outcomes from the SIRONA (Head-to-Head Comparison of SIROlimus versus Paclitaxel Drug-Eluting BallooNAngioplasty in the Femoropopliteal Artery) RCT, which show that its sirolimus-coated balloons (SCB) (MagicTouch -PTA) provide patency and functional benefits on par with paclitaxel-coated balloons for patients suffering from peripheral artery disease (PAD). The 1-year data was presented by Principal Investigator Prof. Ulf Teichgraber at the TCT USA 2024 conference in a Late-Breaking Clinical Trials Session (LBCT). Coverage by TCTMD has highlighted these findings, underscoring sirolimus-based therapy as a viable new option in femoropopliteal interventions.

Jan 07, 2025